Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4’-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2’-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers

Cisplatin is one of the most common therapeutics used in treatments of several types of cancers. To enhance cisplatin lipophilicity and reduce resistance and side effects, a polyfluorinated bipyridine-modified cisplatin analogue, dichloro[4,4’-bis(2,2,3,3-tetrafluoropropoxy)methyl)-2,2’-bipryridine]...

Descripción completa

Detalles Bibliográficos
Autores principales: Kan, Tzu-Chun, Lin, Mei-Hsiang, Cheng, Chun-Chia, Lu, Jeng-Wei, Sheu, Ming-Thau, Ho, Yuan-Soon, Rahayu, Sri, Chang, Jungshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031226/
https://www.ncbi.nlm.nih.gov/pubmed/35456673
http://dx.doi.org/10.3390/pharmaceutics14040839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031226/
https://www.ncbi.nlm.nih.gov/pubmed/35456673
http://dx.doi.org/10.3390/pharmaceutics14040839

Ejemplares similares